Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 04, 2015 3:09 AM ET


Company Overview of Eureka Therapeutics, Inc.

Company Overview

Eureka Therapeutics, Inc., a biotechnology company, focuses on developing immunotherapies for the treatment of cancer. Its product pipeline comprises ESK1, a preclinical-stage monoclonal antibody for the treatment of leukemia and other cancers; ET601, an extracellular tumor antigen; intra and extracellular tumor antigens, immuno-modulatory checkpoints; and intracellular oncogenes. The company’s human antibody products reach inside a cancer cell to recognize cancer-associated proteins and then mobilize the immune system to attack the cancer cell. It also provides contract research services, such as antibody chimerization and humanization, antibody affinity maturation, CHO cell line developmen...

5858 Horton Street

Suite 362

Emeryville, CA 94608

United States

Founded in 2006





Key Executives for Eureka Therapeutics, Inc.

Co-Founder and Chief Executive Officer
Head of Business Operations
Compensation as of Fiscal Year 2015.

Eureka Therapeutics, Inc. Key Developments

Eureka Therapeutics Inc. and Boehringer Ingelheim Announce Collaboration to Identify Next Generation Antibodies for Cancer Treatment

Eureka Therapeutics Inc. and Boehringer Ingelheim announce a collaboration to Identify Next Generation Antibodies for Cancer Treatment. This collaboration underlines long-term commitment to oncology and interest in exploring new target spaces with antibodies that recognize intracellular proteins. It will open up entirely new opportunities for the development of tumor cell- as well as immune cell-targeted therapies. The company are looking forward to working closely with Eureka?s scientists to develop novel, effective therapies targeting cancers that have proved particularly difficult to treat in the past, said Dr. Michel Pairet, Senior Corporate Vice President of Research and Non-clinical Development at Boehringer Ingelheim.

Memorial Sloan Kettering and Eureka Therapeutics Signs Licensing Agreement with Novartis

Memorial Sloan Kettering Cancer Center and Eureka Therapeutics, Inc. announced that it have entered into a licensing agreement with Novartis AG for the development and commercialization of ESK1, a preclinical stage monoclonal antibody for the treatment of leukemia and other cancers. Memorial Sloan Kettering is a cancer hospital that provides cancer care services, while Eureka Therapeutics is a biotechnology company that focuses on the discovery of human antibody drugs for the treatment of cancer. Both the companies are based in the United States. The ESK1 developed by Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center. Under the terms of the agreement, Eureka Therapeutics and Memorial Sloan-Kettering will receive an up front payment and potential future payments upon achievement of development, regulatory and sales milestones, and annual net sales royalty payments. Novartis will fund and execute all additional development and commercialization activities.

Similar Private Companies By Industry

Company Name Region
Precision Genome Engineering, Inc. United States
Abreos Biosciences, Inc. United States
Selenium, Ltd. United States
Divergence, Inc. United States
Corvas International, Inc United States

Recent Private Companies Transactions

Private Placement
August 20, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Eureka Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at